NCT00596115Temporarily Not Available不适用
Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day
Bennett, James P., Jr., M.D., Ph.D.0 个研究点开始时间: 2008年1月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Temporarily Not Available
- 发起方
研究概览
简要总结
R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Definite diagnosis of ALS
排除标准
- •No prior participation in R(+)PPX clinical studies
研究者
相似试验
终止
3 期
Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette SyndromeTourette SyndromeNCT00681863Boehringer Ingelheim45
Unknown
4 期
Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar DisorderBipolar DisorderNCT00325286Creighton University20
终止
2 期
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisNCT00982150Teva Branded Pharmaceutical Products R&D, Inc.446
已完成
2 期
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008Crohn's DiseaseNCT00308438Shire67
已完成
1 期
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETsNeuroendocrine TumorsNCT01590199Novartis Pharmaceuticals18